The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | High-dose carfilzomib recaptures response in r/r multiple myeloma
Xiang Zhou, MD, University Hospital of Würzburg, Würzburg, Germany, discusses results from a study investigating carfilzomib, a second-generation proteasome inhibitor, in patients with relapsed/refractory multiple myeloma. Dosage of carfilzomib depends on what regimen it is part of and the study attempted to elucidate if high-dose carfilzomib can capture response in patients resistant to low-dose carfilzomib. High-dose carfilzomib, defined as 36+ mg/m2, achieved a more robust progression-free survival in patients than low-dose carfilzomib. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
